Experienced Management with established track record of operations and diversified product portfolio
SHIPL was established in 1997 by Mr. Alfred E. Schiller, Chairman of Schiller Healthcare India Private Limited, possesses experience of over four decades and well supported by Mr. Vikram Sanghvi (Managing Director), who has an extensive experience of almost three decades in medical care industry. The extensive experience of the promoters has helped SHIPL to establish a strong brand ‘SCHILLER’ in Indian market as well as SAARC countries. SHIPL caters to government clients such as Tamil Nadu Medical Services Corporation Limited, Odisha State Medical Corporation Limited and among others. Further, SHIPL has diversified product portfolio such as, manufacturing includes OEM manufacturing, trading and servicing of medical equipment. SHIPL manufactures equipment for Cardiology, Critical Care, Monitors and Treadmills. The product mix has also enabled the diversification of risk. Furthermore, the extensive experience of the promoters with a strong brand name has enabled the company to maintain and established long relationships with its customers and suppliers. Acuite believes that business profile of SHIPL will improve over the medium term on account of extensive experience of the management.
Strong financial risk profile
SHIPL’ financial profile is strong as marked by healthy networth, low gearing levels, and comfortable debt protection metrics. The company’s net worth position stood at Rs 95.51 Cr as on March 31, 2023 as against Rs.119.47 Cr as on March 31, 2022. Decline in net worth is mainly on account Rs.40Cr dividends issued by the company during FY23. The capital structure remained healthy with gearing less than 0.40 times and Total Outside Liabilities to Tangible Net Worth (TOL/ TNW) below 1 times for past three years through March 31, 2023 due to limited capex requirements resulting in low external borrowings. The company's coverage indicators are comfortable indicated by interest coverage ratio (ICR) 20.11 times and Net Cash Accruals (NCA)/Total Debt (TD) stood at 2.45 times for FY23 vis-à-vis 2.35 times in FY22. Debt service coverage ratio stood at 4.99 times during FY23 against 13.63 times of previous year.
Acuité believes that financial risk profile will remain healthy over the medium term, supported by healthy accruals, nil long-term debt, and adequate liquidity with no significant debt-funded capital expenditure plans in near future.
|
Adjustment in revenue and profitability to standard levels from all-time highs:
SHIPL’s revenue has declined to Rs. 201.48 Cr in FY23 from Rs.410.78Cr of previous year. The company has registered its all-time highest revenue at Rs410.78Cr during FY22 on account of healthy demand from the healthcare sector owing to covid-19 pandemic. The ample availability of medical equipment has stabilized the demand, leading to adjustment of revenue to its previous range of Rs.200-220Cr post Covid-19 pandemic. Out of the total sales, around 90-95 percent is domestic and remaining is exports to countries like Sri Lanka, Nepal, Burma etc.
The company’s EBITDA margin has also corrected to 11.69 in FY23 percent from all-time high of 16.86 percent. SHIPL continued to show steady growth in its revenue in FY24 as it has reported ~Rs.206Cr till December and expected to close the year in the range of Rs.230-240Cr, while EBITDA margin is expected to be in the range of 12-12.5 percent. Acuite believes that operations of SHIPL will improve over the medium term on account of improving demand.
Intensive working capital operations
SHIPL has working capital intensive nature of operations marked high Gross Current Assets (GCA) days of 270 days in FY23 as against 180 days in FY22. This is majorly due to the collection period of 77 days and high inventory holding period. The stretch in debtor days is because of the elongated manufacturing process (floating tenders, bidding, getting civil work ready, getting necessary approvals, collecting documents, training doctors and taking their feedbacks, verification etc) and government clients. The company’s inventory period surged to 122 days in FY23 as against 54 days for FY23 on account of high inventory of spares in service segment. Despite working capital intensive nature of operations, the utilization of working capital limits remain low around 0-1 percent in last six months ended December, 2023. The Company relies on non- funded based limits, as it needs to furnish bank guarantees to government departments to secure contracts. The same has been utilized at an average of 92 percent during last 12 months ending December 2023. Acuite believes the company’s ability to restrict elongation in its working capital cycle will be a key rating sensitivity.
|